Recombinant Human CXCL17 is a laboratory-engineered version of the naturally occurring chemokine CXCL17, which belongs to the CXC chemokine family. First identified in 2006, CXCL17 is also termed VEGF coregulated chemokine 1 (VCC-1) or dendritic cell- and monocyte-attracting chemokine-like protein (DMC) . The recombinant form is produced in Escherichia coli (E. coli) and retains biological activities such as chemotaxis for monocytes, macrophages, and dendritic cells, along with roles in tumor angiogenesis .
Recombinant CXCL17 is synthesized in E. coli using codon-optimized DNA sequences. Post-expression, it undergoes chromatographic purification (e.g., affinity chromatography for His-tagged variants) and lyophilization. Key steps include:
Purification: Nickel-affinity chromatography followed by buffer exchange .
Quality Control: Validated via SDS-PAGE (>85% purity) and endotoxin testing (<0.1 EU/μg) .
CXCL17 recruits monocytes, immature dendritic cells, and macrophages via GPR35/CXCR8, activating ERK1/2 and p38 signaling pathways . Its chemotactic potency is concentration-dependent, with an ED50 <5 μg/mL in murine endothelial cell assays .
Induces VEGF and FGF production in endothelial cells, promoting tumor vascularization .
Exhibits anti-inflammatory effects in gastric mucosa by suppressing LPS-activated macrophages .
Pro-Tumor Effects: Overexpression in A549 lung cancer cells enhances migration (>60% wound closure at 24 hours) and invasion . Correlated with poor prognosis in breast (60% CXCL17+ cells) and colorectal cancers (50% CXCL17+ cells) .
Therapeutic Target: Linked to drug resistance in colorectal cancer and Akt pathway activation in cervical cancer .
CXCL17 exhibits dual roles in disease: